SA
SONM icon

Sicart Associates’s DNA X Inc SONM Stock Holding History

Sicart Associates’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,260
Closed -$407K – 77
2024
Q2 		$407K Sell
2,260
-34
-1% -$3.7K 0.16% 54
2024
Q1 		$252K Hold
2,294
– – 0.09% 67
2023
Q4 		$304K Hold
2,294
– – 0.12% 60
2023
Q3 		$277K Buy
2,294
+1,066
+87% +$149K 0.11% 58
2023
Q2 		$254K Buy
1,228
+117
+11% +$22.8K 0.1% 59
2023
Q1 		$202K Buy
+1,111
New +$104K 0.08% 65

Other funds holding SONM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Sicart Associates's SONM Position: Q3 2024 in Review

Sicart Associates sold out of DNA X Inc (SONM) in Q3 2024, closing a stake of 2,260 shares — an estimated $407K sold.

Sicart Associates first reported a position in SONM in Q1 2023 and held it in 6 quarters. The position peaked at $407K in Q2 2024. 8 funds tracked by Wall St. Rank hold SONM as of Q3 2024.

  • Sicart Associates reported no remaining DNA X Inc position as of Q3 2024 after selling out during the quarter.
  • Sicart Associates sold 2,260 DNA X Inc shares in Q3 2024, an estimated $407K.
  • Sicart Associates first reported a position in DNA X Inc in Q1 2023 and held it in 6 quarters.
  • Sicart Associates's DNA X Inc position peaked at $407K in Q2 2024.
  • 8 funds tracked by Wall St. Rank held DNA X Inc as of Q3 2024.

Based on Sicart Associates's 13F filing for Q3 2024, filed 25 Oct 2024.